These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 17410043)

  • 21. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
    Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
    Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706.
    Takeda K; Negoro S; Tanaka M; Fukuda H; Nakagawa K; Kawahara M; Semba H; Kudoh S; Sawa T; Saijo N; Fukuoka M
    Jpn J Clin Oncol; 2011 Jan; 41(1):25-31. PubMed ID: 20802006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation.
    Choy H; Yee L; Cole BF
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):38-44. PubMed ID: 8643969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Report of phase II trial of concurrent chemoradiotherapy with radical thoracic irradiation (60 Gy), infusional fluorouracil, bolus cisplatin and etoposide for clinical stage IIIB and bulky IIIA non-small cell lung cancer.
    Langer CJ; Curran WJ; Keller SM; Catalano R; Fowler W; Blankstein K; Litwin S; Bagchi P; Nash S; Comis R
    Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):469-78. PubMed ID: 8390421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer.
    Ilson DH; Bains M; Kelsen DP; O'Reilly E; Karpeh M; Coit D; Rusch V; Gonen M; Wilson K; Minsky BD
    J Clin Oncol; 2003 Aug; 21(15):2926-32. PubMed ID: 12885811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
    Liu D; Zheng X; Chen J; Liu G; Xu Y; Shen Y; Xie L; Zhao W; Jiang G; Fan M
    Lung Cancer; 2015 Sep; 89(3):249-54. PubMed ID: 26118463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer.
    Center B; Petty WJ; Ayala D; Hinson WH; Lovato J; Capellari J; Oaks T; Miller AA; Blackstock AW
    J Thorac Oncol; 2010 Jan; 5(1):69-74. PubMed ID: 20035186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancer.
    Fujita A; Takabatake H; Tagaki S; Sekine K
    Cancer Chemother Pharmacol; 2000; 45(4):279-83. PubMed ID: 10755315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.
    Socinski MA; Morris DE; Halle JS; Moore DT; Hensing TA; Limentani SA; Fraser R; Tynan M; Mears A; Rivera MP; Detterbeck FC; Rosenman JG
    J Clin Oncol; 2004 Nov; 22(21):4341-50. PubMed ID: 15514375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: a dose finding study.
    Mudad R; Ramsey M; Kovitz K; Curiel TJ; Hartz R; Nedzi LL; Weiner RS; Zakris EL
    Lung Cancer; 2003 Feb; 39(2):173-7. PubMed ID: 12581570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.
    Han JY; Lee DH; Kim HY; Kim EA; Lee JJ; Ju SY; Shin EH; Lee JS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5909-14. PubMed ID: 14676114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accelerated-interrupted radiation therapy given concurrently with chemotherapy for locally advanced non-small cell lung cancer.
    Ajlouni M; Chapman R; Kim JH
    Cancer J Sci Am; 1996; 2(6):314-20. PubMed ID: 9166551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
    Frasci G; Comella P; Thomas R; Di Bonito M; Lapenta L; Capasso I; Botti G; Vallone P; De Rosa V; D'Aiuto G; Comella G
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):25-32. PubMed ID: 14513281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of oral S-1 plus Cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
    Kaira K; Sunaga N; Yanagitani N; Kawata T; Utsugi M; Shimizu K; Ebara T; Kawamura H; Nonaka T; Ishikawa H; Sakurai H; Suga T; Hara K; Hisada T; Ishizuka T; Nakano T; Mori M
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):109-14. PubMed ID: 18929446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Irinotecan and cisplatin with concurrent thoracic radiotherapy in a once-every-three-weeks schedule in patients with limited-disease small-cell lung cancer: a phase I study.
    de Jong WK; de Jonge MJ; van der Leest AH; van Meerbeeck JP; Groen HJ
    Lung Cancer; 2008 Jul; 61(1):123-8. PubMed ID: 18179842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of twice-daily high-dose thoracic radiotherapy alternating with cisplatin and vindesine for unresectable stage III non-small-cell lung cancer: Japan Clinical Oncology Group Study 9306.
    Sekine I; Nishiwaki Y; Ogino T; Yokoyama A; Saito M; Mori K; Tsukiyama I; Tsuchiya S; Hayakawa K; Yoshimura K; Ishizuka N; Saijo N
    J Clin Oncol; 2002 Feb; 20(3):797-803. PubMed ID: 11821463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapy.
    Kim HT; Han JY; Lee DH; Chun JH; Lee HG; Lee JJ; Kim HY; Lee SY; Lee JS
    Cancer; 2006 Aug; 107(4):799-805. PubMed ID: 16826586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer.
    Fukuda M; Nakamura Y; Kinoshita A; Soejima Y; Yamaguchi H; Ikeda T; Izumikawa K; Takatani H; Fukuda M; Soda H; Hayashi N; Tsukamoto K; Oka M; Kohno S
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):645-51. PubMed ID: 23010852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.